| Open Document File Size: 1,03 MBShare Result on Facebook
Company GE / Immunex / / Event FDA Phase / / Facility Chi Square / / IndustryTerm open-label extension protocol / iniection site / / MedicalCondition aseptic meningitis / abdominal pain / Vaginitis / pneumonia / Baker’s cyst / Accidental Injury / Skin infection / disease / Cystitis / headache / personality disorder / hyperpigmentation / Flu / herpes zoster / gastroenteritis / varicella infection / I Abdominal pain / recurrent peptic ulcer disease / arthritis / Esophagitis / Bronchitis / infectious episodes / cellulitis / nausea / Mouth ulcer / rhinitis / urethritis / Appendicitis (unrelated) Arthritis / Lethargy / Infectious Adverse Even1 / Conjunctivitis / pain / vomiting / prostatitis / urticaria / gastritis / Number Gastroenteritis / frequent upper respiratory infections / Diarrhea / related connective tissue disease / infection / SLE / Sinusitis / Dizziness / Otitis media / tracheitis / Cough / severe disease / thrombosis / infections / varicella / vasculitic rash / infectious disease / Pharyngitis / infectious adverse events / baseline disease / abscess / MCTD / JRA disease / / Product ENBREL / D. Injection / Corticosteroid injection / naproxen sodium / DO1 / / Technology Antibodies / open-label extension protocol / /
SocialTag |
Responses to ENBREL in Part 1: Open label. Results of patients receiving open-label ENBREL for 3 months are summarized in Table 26. Last observation *tied forward analysis is used, classifying dropouts as non-responders.